The anti-MMP14 inhibitory antibody can inhibit tumor growth, reduce tissue hypoxia, increase macrophage number, and shift cell phenotype towards the more anti-tumor M1-like phenotype due to reduced active TGFβ and SMAD2/3 signaling, hence synergistically enhancing RT effects (Figure 2) [171]. The gene discussed is SMAD2; the disease is neoplasm.